Table 2.
Univariate association of urinary phthalate metabolites with self-reported eye affliction/retinopathy in participants with diabetes, NHANES 2001–2010†,∗.
| Phthalate | OR | 95% CI | P ∗∗ | P c ∗∗ |
|---|---|---|---|---|
| Mono-n-butyl (MBP) | 1.12 | 0.90–1.39 | 0.285 | 1.000 |
| Mono-cyclohexyl (MCP) | 1.28 | 0.99–1.63 | 0.053 | 0.636 |
| Mono-ethyl (MEP) | 1.08 | 0.83–1.40 | 0.583 | 1.000 |
| Mono-(2-ethyl)-hexyl (MEHP) | 1.02 | 0.83–1.25 | 0.860 | 1.000 |
| Mono-isononyl (MNP) | 1.19 | 0.95–1.49 | 0.120 | 1.000 |
| Mono-n-octyl (MOP) | 1.39 | 1.11–1.74 | 0.004 | 0.048 |
| Mono-benzyl (MBzP) | 1.20 | 0.91–1.57 | 0.196 | 1.000 |
| Mono-n-methyl (MNM) | 1.10 | 0.85–1.42 | 0.455 | 1.000 |
| Mono-(3-carboxypropyl) (MCPP) | 1.01 | 0.83–1.24 | 0.893 | 1.000 |
| Mono-(2-ethyl-5-hydroxyhexyl) (MEHHP) | 1.17 | 0.93–1.46 | 0.176 | 1.000 |
| Mono-(2-ethyl-5-oxohexyl) (MEOHP) | 1.22 | 0.97–1.54 | 0.084 | 1.000 |
| Mono-isobutyl (MiBP) | 1.14 | 0.90–1.45 | 0.278 | 1.000 |
†All models account for the survey design variables using svy command in Stata and use inverse-normalized concentrations of phthalate metabolites.
∗Results are from separate logistic regression models for each phthalate metabolite.
∗∗ P: nominal significance value; P c: Bonferroni-corrected significance value.